Formoterol porous particle
Alternative Names: FF MDI; PT-005Latest Information Update: 02 Oct 2021
At a glance
- Originator Pearl Therapeutics
- Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 31 Aug 2017 Pearl Therapeutics completes a phase III trial in Chronic obstructive pulmonary disease in Hungary, Poland, Czech Republic, Germany, United Kingdom, USA (Inhalation) (NCT02343458) (EudraCT2014-004712-10)
- 30 Sep 2016 Discontinued - Phase-III for Chronic obstructive pulmonary disease in Australia, New Zealand, USA (Inhalation)
- 01 Mar 2015 Pearl Therapeutics completes a phase II trial for Chronic obstructive pulmonary disease in USA (NCT02196077)